RNAi News and Research

RSS

Yale-led study reveals new factors that contribute to hardening of arteries and plaque growth

In a new Yale-led study, investigators have revealed previously unknown factors that contribute to the hardening of arteries and plaque growth, which cause heart disease.

26 Aug 2019

FACS-based CRISPR screening shows how Chlamydia bacterium invades host cells

Using FACS-based CRISPR screening, scientists have identified three candidate genes that may facilitate the invasion of Chlamydia trachomatis into host cells.

19 Jun 2019

Plant-derived siRNAs could bring a 'green revolution' in RNAi tools and therapeutics

"Green revolution" in the early 1950s, the extensive cultivation of Dwarf Rice solves the food problem in developing countries. At present, chronic infection with hepatitis B virus (HBV) has been a major public health problem.

11 Jun 2019

Biologists unravel new role for nervous system in regeneration

Biologists at Tufts University have developed a computational model of planarian (flatworm) regeneration that explains how fragments of planaria determine which end should form a tail and which should form a head.

25 Apr 2019

Study describes vulnerability shared by large subset of cancer cell lines

Cancer cells adapt to potentially fatal mutations and other molecular malfunctions by adjusting one or more other genes' activity, in the process becoming dependent on those genes for their survival and growth.

12 Apr 2019

Large-scale screen efficiently identifies drugs that are potent cancer-killers

UC San Francisco scientists have designed a large-scale screen that efficiently identifies drugs that are potent cancer-killers when combined, but only weakly effective when used alone.

10 Apr 2019

UTMB receives grant to combat highly-lethal hemorrhagic fever viruses

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.

9 Apr 2019

Liver tissue model can help investigate the effects of RNA interference

Novel therapies based on a process known as RNA interference hold great promise for treating a variety of diseases by blocking specific genes in a patient's cells. Many of the earliest RNAi treatments have focused on diseases of the liver, because RNA-carrying particles tend to accumulate in that organ.

6 Mar 2019

Researchers outline targeted therapeutic strategy for triple-negative breast cancer

New findings put forth by the University of Maryland Fischell Department of Bioengineering and researchers from four other academic institutions outline a targeted therapeutic strategy to treat triple-negative breast cancer - a potential first for the particularly aggressive form of breast cancer.

26 Feb 2019

New acute porphyria treatment shows promising results in clinical study

Acute porphyria is a group of uncommon diseases that can cause severe, potentially life-threatening attacks of abdominal pain, nausea, vomiting and paralysis. Liver transplantation is currently the only effective treatment available for the most seriously afflicted patients.

7 Feb 2019

RBSC announces partnership with Mitacs to develop and test yeast-based RNAi technology

Renaissance BioScience Corp., a leading global microorganism bioengineering company, is pleased to announce a new partnership with Mitacs, the University of British Columbia and the University of Manitoba for a three-year, Cdn$975,000 multi-investigator research and development project.

24 Jan 2019

Protein discovery could lead to mosquito "birth control"

Researchers have discovered a way of preventing mosquito eggs from hatching, paving the way for drugs that could serve as “birth control” within mosquito populations.

9 Jan 2019

Inhalable mRNA offers hope for patients with lung disease

Scientists have reported the success of an inhalable mRNA therapy that can induce the production of a target protein in the lungs of mice.

4 Jan 2019

Genetically modified pigs could limit replication of classical swine fever virus, study shows

Researchers have developed genetically modified pigs that are protected from classical swine fever virus, according to a study published December 13 in the open-access journal PLOS Pathogens by Hongsheng Ouyang of Jilin University, and colleagues.

14 Dec 2018

Novel DNA nanoplatform delivers anticancer agents to multidrug-resistant tumors

One of the most successful techniques to combat multidrug resistance in cancer cells is the downregulation of those genes responsible for drug resistance.

22 Nov 2018

RNAi therapy shown to alleviate preeclampsia in animal model

Researcher have used a small interfering RNA (siRNA) to reduce preeclampsia symptoms in an animal model. The approach could provide a new way of treating preeclampsia in humans.

19 Nov 2018

New initiative may benefit entrepreneurs working to transform patient care

Entrepreneurs working to improve the lives and promote the independence of patients may soon benefit from an initiative run by the Massachusetts Medical Device Development Center.

9 Nov 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).